NO178029C - Analogifremgangsmåte ved fremstilling av terapeutisk aktive pyrazolopyrimidinoner - Google Patents

Analogifremgangsmåte ved fremstilling av terapeutisk aktive pyrazolopyrimidinoner

Info

Publication number
NO178029C
NO178029C NO912366A NO912366A NO178029C NO 178029 C NO178029 C NO 178029C NO 912366 A NO912366 A NO 912366A NO 912366 A NO912366 A NO 912366A NO 178029 C NO178029 C NO 178029C
Authority
NO
Norway
Prior art keywords
alkyl
cycloalkyl
alkoxy
perfluoroalkyl
pyrazolopyrimidinones
Prior art date
Application number
NO912366A
Other languages
English (en)
Norwegian (no)
Other versions
NO912366L (no
NO912366D0 (no
NO178029B (no
Inventor
Andrew Simon Bell
David Brown
Nicholas Kenneth Terrett
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10677918&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO178029(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NO912366D0 publication Critical patent/NO912366D0/no
Publication of NO912366L publication Critical patent/NO912366L/no
Publication of NO178029B publication Critical patent/NO178029B/no
Publication of NO178029C publication Critical patent/NO178029C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G05—CONTROLLING; REGULATING
    • G05B—CONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
    • G05B2219/00—Program-control systems
    • G05B2219/30—Nc systems
    • G05B2219/36—Nc in input of data, input key till input tape
    • G05B2219/36395—Load local computer program from host, data transfer ram to rom, BTR

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO912366A 1990-06-20 1991-06-18 Analogifremgangsmåte ved fremstilling av terapeutisk aktive pyrazolopyrimidinoner NO178029C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909013750A GB9013750D0 (en) 1990-06-20 1990-06-20 Therapeutic agents

Publications (4)

Publication Number Publication Date
NO912366D0 NO912366D0 (no) 1991-06-18
NO912366L NO912366L (no) 1991-12-23
NO178029B NO178029B (no) 1995-10-02
NO178029C true NO178029C (no) 1996-01-10

Family

ID=10677918

Family Applications (2)

Application Number Title Priority Date Filing Date
NO912366A NO178029C (no) 1990-06-20 1991-06-18 Analogifremgangsmåte ved fremstilling av terapeutisk aktive pyrazolopyrimidinoner
NO1999004C NO1999004I2 (no) 1990-06-20 1999-03-16 Sildenafil

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1999004C NO1999004I2 (no) 1990-06-20 1999-03-16 Sildenafil

Country Status (31)

Country Link
EP (1) EP0463756B1 (cs)
JP (1) JPH07121945B2 (cs)
KR (1) KR940006628B1 (cs)
CN (1) CN1028758C (cs)
AT (1) ATE121403T1 (cs)
AU (1) AU626757B2 (cs)
BR (1) BR9102560A (cs)
CA (1) CA2044748C (cs)
CY (2) CY1971A (cs)
CZ (1) CZ279289B6 (cs)
DE (2) DE19975015I2 (cs)
DK (1) DK0463756T3 (cs)
EG (1) EG19651A (cs)
ES (1) ES2071919T4 (cs)
FI (1) FI95132C (cs)
GB (1) GB9013750D0 (cs)
HK (1) HK219496A (cs)
HU (1) HU218945B (cs)
IE (1) IE66040B1 (cs)
IL (1) IL98482A (cs)
LU (1) LU90360I2 (cs)
MY (1) MY107176A (cs)
NL (1) NL990005I2 (cs)
NO (2) NO178029C (cs)
NZ (1) NZ238586A (cs)
PL (1) PL166490B1 (cs)
PT (1) PT98011B (cs)
RU (2) RU2114114C1 (cs)
TW (1) TW222633B (cs)
YU (1) YU47962B (cs)
ZA (1) ZA914707B (cs)

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0193801A (ja) * 1987-10-05 1989-04-12 Fanuc Ltd コントロールプログラムのローディング装置
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) * 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
DE4211239C2 (de) * 1992-04-03 1995-11-16 Max Planck Gesellschaft Arzneimittel gegen Herz-Kreislauf-Erkrankungen
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
JP3726306B2 (ja) * 1994-04-27 2005-12-14 日産化学工業株式会社 ピラゾールカルボン酸誘導体および植物病害防除剤
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
PL322452A1 (en) * 1995-03-10 1998-02-02 Sanofi Pharmaceuticals 6-arylpyrasole [3,4-d]pyrimidin-4-ones, preparations containing such compounds and methods of mking use of them
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
CZ358598A3 (cs) 1996-05-10 1999-03-17 Icos Corporation Karbolinové deriváty
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
HRP970348A2 (en) * 1996-07-17 1998-04-30 Bayer Ag New nitropyrazole esters, process for their preparation and their use for the preparation of nytropyrazolamides
WO1998019672A1 (en) * 1996-11-01 1998-05-14 Nitromed Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
USRE37234E1 (en) * 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
DE19701277A1 (de) * 1997-01-16 1998-07-23 Bayer Ag Verfahren zur Herstellung von 1-Alkyl-pyrazol-5-carbonsäureestern
KR100441229B1 (ko) 1997-04-25 2004-07-22 화이자 인코포레이티드 타입 5 시클릭 구아노신 3',5'-모노포스페이트 포스포디에스테라제(ｃＧＭＰ ＰＤＥ5)를 억제하는 성기능 장애 치료용 피라졸로피리미디논
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
US20020025969A1 (en) * 1997-07-09 2002-02-28 Wolf-Georg Forssmann Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
DE19750085A1 (de) * 1997-11-12 1999-05-20 Bayer Ag 2-Phenyl-substituierte Imidazotriazinone
SK287161B6 (sk) 1997-11-12 2010-02-08 Bayer Healthcare Ag 2-Fenylsubstituované imidazotriazinóny, spôsob ich výroby, liečivá obsahujúce tieto látky a ich použitie
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
ES2242124T3 (es) * 1998-04-20 2005-11-01 Pfizer Inc. Derivados del acido piridin-3-carboxilico y su uso como productos intermedios.
CA2235642C (en) 1998-05-15 2007-11-13 Torcan Chemical Ltd. Processes for preparing sildenafil
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
DE19829616A1 (de) 1998-07-02 2000-01-05 Bayer Ag Verfahren zur Herstellung von 1-Alkyl-pyrazol-5-carbonsäureestern
DE19834506A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
GB9822238D0 (en) * 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
JP2002528456A (ja) * 1998-10-23 2002-09-03 ファイザー・インク 性的機能障害の処置のためのピラゾロピリミジノン系ｃＧＭＰ阻害薬
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
RU2220145C2 (ru) * 1998-11-11 2003-12-27 Донг А Фарм. Ко., Лтд. Производные пиразолопиримидинона для лечения импотенции и способ их получения
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
EP1002798A1 (en) * 1998-11-20 2000-05-24 Orchid Chemicals & Pharmaceuticals Ltd. An improved process for preparing a therapeutically active pyrazolopyrimidinone derivative
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
WO2000044363A2 (en) * 1999-01-28 2000-08-03 Sepracor Inc. Desmethylsildenafil compositions and uses for treating angina and erectile dysfunctions
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
AU3248600A (en) * 1999-03-03 2000-09-21 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
CN1094492C (zh) * 1999-06-21 2002-11-20 杭州神鹰医药化工有限公司 西地那非的制备方法
AU5204800A (en) * 1999-06-21 2001-01-09 Biochemical Pharmaceutical Factory of Zhuhai Sez, The Process for preparing sildenafil, and troche which comprises sildenafil and apomorphine
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
CN1077108C (zh) * 1999-07-13 2002-01-02 成都地奥制药集团有限公司 用于制备药物昔多芬的前体化合物
IL130968A (en) * 1999-07-15 2002-12-01 Shmuel Simon Pharmaceutical composition comprising sildenafil or its analogs, useful for the treatment of tinnitus and hearing loss
ES2166270B1 (es) 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
EP1077214A1 (en) * 1999-08-16 2001-02-21 Orchid Chemicals & Pharmaceuticals Ltd. An improved process for preparing a pyrazolopyrimidinone derivative
WO2001019827A1 (en) * 1999-09-13 2001-03-22 Cipla Ltd. A novel process for the synthesis of sildenafil citrate
EA200200240A1 (ru) * 1999-10-11 2002-10-31 Пфайзер Инк. 5-(2-ЗАМЕЩЕННЫЕ-5-ГЕТЕРОЦИКЛИЛСУЛЬФОНИЛПИРИД-3-ИЛ)-ДИГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-7-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
CA2395548A1 (en) 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Imidazo 1,3,5 triazinones and the use thereof
DE50008549D1 (de) 1999-12-24 2004-12-09 Bayer Healthcare Ag Triazolotriazinone und ihre verwendung
US6777416B2 (en) 1999-12-24 2004-08-17 Bayer Aktiengesellschaft Isoxazolo pyrimidinones and the use thereof
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
WO2001087888A1 (en) * 2000-05-17 2001-11-22 Sk Chemicals Co., Ltd. Pyrazolopyrimidinone derivatives, process for their preparation and their use
US6730786B2 (en) 2000-06-22 2004-05-04 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
MXPA02012887A (es) * 2000-06-22 2003-05-14 Pfizer Nuevo procedimiento para la preparacion de pirazolopirimidinonas.
GB0015462D0 (en) * 2000-06-22 2000-08-16 Pfizer Ltd Novel process for the preparation of pyrazolopyrimidinones
US6667398B2 (en) 2000-06-22 2003-12-23 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
KR100377782B1 (ko) * 2000-06-23 2003-03-29 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법
EP1176147A1 (en) * 2000-07-28 2002-01-30 Pfizer Limited Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof
EP1176142A1 (en) * 2000-07-28 2002-01-30 Pfizer Inc. Process for the preparation of pyrazoles
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US6809200B2 (en) 2000-07-28 2004-10-26 Pfizer Inc. Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof
CN1446084A (zh) * 2000-08-11 2003-10-01 辉瑞大药厂 胰岛素抗性综合症的治疗
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
WO2002016364A1 (en) * 2000-08-23 2002-02-28 Lg Life Sciences Ltd. Polyethoxylated pyrazolo pyrimidinone derivatives, process for preparation thereof and pharmaceutical compositions comprising the same for the treatment of impotence
HK1053129A1 (zh) * 2000-09-06 2003-10-10 Ortho-Mcneil Pharmaceutical, Inc. 治疗变态反应的方法
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
EP1211313A3 (en) * 2000-11-01 2003-04-23 Pfizer Limited Modulation of PDE11A activity
US6828473B2 (en) 2000-11-01 2004-12-07 Pfizer Inc. Modulation of PDE11A activity
SE0004780D0 (sv) 2000-12-22 2000-12-22 Jordanian Pharmaceutical Mfg & Novel compunds
DE10118306A1 (de) 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
CN1127506C (zh) * 2001-06-29 2003-11-12 刘宝顺 一种治疗阳痿的新化合物
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
RU2278863C2 (ru) * 2001-08-10 2006-06-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция и способ ингибирования активности катепсина s
RU2286343C2 (ru) * 2001-08-10 2006-10-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
DE60226615D1 (cs) 2001-08-28 2008-06-26 Schering Corp
DE10155018A1 (de) * 2001-11-07 2003-07-10 Berolina Drug Dev Ab Svedala Deuterierte Pyrazolopyrimidinone sowie diese Verbindungen enthaltende Arzneimittel
WO2003042216A1 (en) 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
ES2294189T3 (es) 2001-12-13 2008-04-01 Asubio Pharma Co., Ltd. Derivados de pirazolopirimidinona que tienen accion inhibidora de pde7.
WO2003053923A2 (en) 2001-12-20 2003-07-03 Applied Research Systems Ars Holding N.V. Pyrrolidine derivatives as prostaglandin modulators
GB0202282D0 (en) 2002-01-31 2002-03-20 Pfizer Ltd Treatment of male sexual dysfunction
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
KR100435514B1 (ko) * 2002-03-22 2004-06-10 한미약품 주식회사 실데나필 젖산염의 속효제형
DK1348707T3 (da) * 2002-03-28 2010-12-13 Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP2005529927A (ja) * 2002-05-23 2005-10-06 ファイザー インコーポレイテッド 新規な組み合わせ
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
WO2004103407A2 (en) 2003-05-22 2004-12-02 Altana Pharma Ag Composition comprising a pde4 inhibitor and a pde5 inhibitor
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2007504243A (ja) * 2003-09-03 2007-03-01 ニューロジェン・コーポレーション ５−アリール−ピラゾロ［４，３−ｄ］ピリミジン類、ピリジン類、ピラジン類及び関連化合物
EP1779852A3 (en) * 2004-01-05 2007-05-09 Teva Pharmaceutical Industries Ltd. Processes for the production of sildenafil base and citrate salt
PL1633364T3 (pl) * 2004-01-05 2008-07-31 Teva Pharma Sposób wytwarzania zasady sildenafilu i cytrynianu sildenafilu
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
JP5070052B2 (ja) * 2004-08-17 2012-11-07 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
UA84688C2 (uk) * 2005-04-15 2008-11-25 Виктор Павлович Кутняк Засіб для лікування еректильної дисфункції
KR101358479B1 (ko) 2005-04-19 2014-02-06 다케다 게엠베하 폐고혈압 치료용 로플루밀라스트
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US8071765B2 (en) 2006-12-21 2011-12-06 Topharman Shanghai Co., Ltd. Process for the preparation of sildenafil and intermediates thereof
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2310144B1 (es) 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
WO2009053854A2 (en) 2007-10-23 2009-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
BRPI0823356A2 (pt) 2008-12-12 2015-06-16 Rhein Siegfried Sa De Cv Composição de liberação pulsátil de sildenafil e processo para prepará-la
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
WO2010074783A1 (en) 2008-12-23 2010-07-01 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
NZ625983A (en) 2009-11-27 2016-02-26 Adverio Pharma Gmbh Method for producing methyl-{ 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate and its purification for use thereof as pharmaceutical substance
CN101870699B (zh) * 2010-04-06 2013-11-20 漆又毛 苯磺酰基哌嗪衍生物
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
MX2010006227A (es) 2010-06-07 2011-12-14 World Trade Imp Exp Wtie Ag Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
WO2012000634A1 (de) 2010-06-29 2012-01-05 Georg Bambach Pharmazeutische zusammensetzung zur behandlung von erektiler dysfunktion
CN101891747B (zh) * 2010-07-02 2012-04-25 张南 抑制5型磷酸二酯酶的化合物及制备方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
PT2896617T (pt) 2011-11-25 2016-11-18 Adverio Pharma Gmbh Processo para a preparação de (z)-alpha-fluoro-betaaminoacrilamidas substituidas
WO2014030716A1 (ja) * 2012-08-23 2014-02-27 田辺三菱製薬株式会社 ピラゾロピリミジン化合物
BR112015019571A2 (pt) 2013-02-21 2017-07-18 Adverio Pharma Gmbh formas de {4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridino-3-il]pirimidino-5-il}metilcarbamato de metila
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
KR20160042039A (ko) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
CN103755709B (zh) * 2014-01-15 2016-05-25 广东药学院 西地那非衍生物的微波辅助制备方法
CN105017255A (zh) * 2014-04-25 2015-11-04 浙江泰康药业集团有限公司 西地那非制备工艺
EP3157520B1 (en) 2014-06-23 2019-09-04 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
CN107880048A (zh) * 2015-07-23 2018-04-06 青岛华之草医药科技有限公司 一种枸橼酸西地那非化合物
DK3377495T3 (da) 2015-11-16 2022-05-09 Topadur Pharma Ag 2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinon-derivativer som phosphodiesterasehæmmere og anvendelser deraf
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
US11969462B2 (en) 2017-06-21 2024-04-30 Transgene Personalized vaccine
AU2019229653B2 (en) 2018-03-07 2025-09-11 Transgene Parapoxvirus vectors
CN112566670B (zh) 2018-08-06 2024-11-12 尼科斯股份有限公司 一氧化氮释放第5型磷酸二酯酶抑制剂
SE542968C2 (en) 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis
BR112021009958A2 (pt) 2018-11-28 2021-08-17 Topadur Pharma Ag modo duplo de ação de ativadores de guanilato ciclase solúveis e inibidores de fosfodiesterase e seus usos
IL284421B2 (en) 2018-12-28 2025-05-01 Transgene M2-defective poxvirus
EP3972599A1 (en) 2019-05-21 2022-03-30 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
CN118878542A (zh) * 2024-07-16 2024-11-01 西安市食品药品检验所 一种豪莫西地那非衍生物及其合成方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators

Also Published As

Publication number Publication date
PT98011A (pt) 1992-03-31
IL98482A0 (en) 1992-07-15
HUT61312A (en) 1992-12-28
CY1971A (en) 1997-09-05
YU108791A (sh) 1994-01-20
KR920000761A (ko) 1992-01-29
BR9102560A (pt) 1992-01-21
DE19975015I2 (de) 2006-03-16
CA2044748A1 (en) 1991-12-21
AU7915591A (en) 1992-03-19
CS187691A3 (en) 1992-04-15
PT98011B (pt) 1997-04-30
PL290721A1 (en) 1992-03-23
CZ279289B6 (cs) 1995-04-12
FI913017A7 (fi) 1991-12-21
LU90360I2 (fr) 1999-05-03
IL98482A (en) 1995-11-27
DE69108991D1 (de) 1995-05-24
ES2071919T4 (es) 2011-08-30
PL166490B1 (pl) 1995-05-31
ES2071919T3 (es) 1995-07-01
KR940006628B1 (ko) 1994-07-23
IE66040B1 (en) 1995-12-13
ATE121403T1 (de) 1995-05-15
NL990005I1 (nl) 1999-05-03
JPH0641133A (ja) 1994-02-15
GB9013750D0 (en) 1990-08-08
EP0463756A1 (en) 1992-01-02
JPH07121945B2 (ja) 1995-12-25
DE69108991T2 (de) 1995-08-31
RU2114114C1 (ru) 1998-06-27
NL990005I2 (nl) 1999-06-01
HU218945B (hu) 2001-01-29
EG19651A (en) 1995-10-31
TW222633B (cs) 1994-04-21
NO912366L (no) 1991-12-23
FI95132C (fi) 1995-12-27
NO1999004I2 (no) 2012-06-04
AU626757B2 (en) 1992-08-06
CN1057464A (zh) 1992-01-01
DK0463756T3 (da) 1995-09-25
HU912061D0 (en) 1991-12-30
ZA914707B (en) 1993-02-24
YU47962B (sh) 1996-07-24
CY99011I2 (en) 2010-07-28
NO912366D0 (no) 1991-06-18
FI913017A0 (fi) 1991-06-19
EP0463756B1 (en) 1995-04-19
HK219496A (en) 1997-01-03
MY107176A (en) 1995-09-30
CA2044748C (en) 1998-02-03
NZ238586A (en) 1993-08-26
CN1028758C (zh) 1995-06-07
NO178029B (no) 1995-10-02
FI95132B (fi) 1995-09-15
IE912094A1 (en) 1992-01-01
RU2047617C1 (ru) 1995-11-10

Similar Documents

Publication Publication Date Title
NO178029C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive pyrazolopyrimidinoner
GB9114760D0 (en) Therapeutic agents
GB9213623D0 (en) Therapeutic agents
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler

Legal Events

Date Code Title Description
MK1K Patent expired
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: SILDENAFIL; NAT. REG. NO/DATE: 98/1704-1706 19981109; FIRST REG. NO/DATE: CH 54642 01 19980622

Spc suppl protection certif: 1999004

Filing date: 19990316

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: SILDENAFIL; NAT. REG. NO/DATE: 98/1704-1706 19981109; FIRST REG. NO/DATE: CH 54642 01 19980622

Spc suppl protection certif: 1999004

Filing date: 19990216

Extension date: 20130622

Effective date: 20120525

SPCX Expiry of an spc

Spc suppl protection certif: 1999004

Effective date: 20130622